$-0.40 EPS Expected for InflaRx N.V. (IFRX); Ternium S.A. (TX) Covered By 2 Bullish Analysts Last Week




July 30, 2018 – By Ashley Bratcher

Ternium S.A. (NYSE:TX) Logo

Among 2 analysts covering Ternium SA (NYSE:TX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ternium SA had 3 analyst reports since February 8, 2018 according to SRatingsIntel. As per Thursday, February 8, the company rating was maintained by Scotia Capital. Scotia Capital maintained Ternium S.A. (NYSE:TX) rating on Thursday, April 19. Scotia Capital has “Buy” rating and $4700 target. Credit Suisse upgraded the shares of TX in report on Tuesday, May 15 to “Outperform” rating. See Ternium S.A. (NYSE:TX) latest ratings:

15/05/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Outperform Upgrade
19/04/2018 Broker: Scotia Capital Rating: Buy New Target: $47.0000 Maintain
08/02/2018 Broker: Scotia Capital Rating: Buy New Target: $43.0 Maintain

Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.40 EPS on August, 16.After having $-0.49 EPS previously, InflaRx N.V.’s analysts see -18.37% EPS growth. The stock decreased 0.69% or $0.21 during the last trading session, reaching $30.44. About 3,421 shares traded. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since July 30, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical IFRX News: 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $781.15 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Seekingalpha.com which released: “Biotech: Take It On The Run” on July 05, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on July 13, 2018, Schaeffersresearch.com published: “3 Healthcare Stocks Making Massive Moves” on July 13, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Streetinsider.com and their article: “BMO Capital Starts Inflarx NV (IFRX) at Outperform” published on July 13, 2018 as well as Benzinga.com‘s news article titled: “30 Stocks Moving In Friday’s Mid-Day Session” with publication date: July 13, 2018.

More news for Ternium S.A. (NYSE:TX) were recently published by: Seekingalpha.com, which released: “Nucor: Leveraging Higher Prices And Prior Growth Investments” on July 26, 2018. Nasdaq.com‘s article titled: “5 New Strong Buy Stocks for July 16th” and published on July 16, 2018 is yet another important article.

Ternium S.A. manufactures and processes various steel products in Mexico, Argentina, Bolivia, Chile, Paraguay, Uruguay, Colombia, the United States, Central America, and internationally. The company has market cap of $7.16 billion. The firm operates in two divisions, Steel and Mining. It has a 7.22 P/E ratio. The Steel segment offers steel products, such as slabs, billets and round bars, hot-rolled coils and sheets, bars and stirrups, wire rods, cold-rolled coils and sheets, tin plates, hot dipped galvanized and electrogalvanized sheets, pre-painted sheets, steel pipes and tubular products, beams, roll formed products, and other products.

The stock increased 0.03% or $0.01 during the last trading session, reaching $36.47. About 227,175 shares traded. Ternium S.A. (NYSE:TX) has risen 46.05% since July 30, 2017 and is uptrending. It has outperformed by 33.48% the S&P500. Some Historical TX News: 25/04/2018 – Ternium 1Q EPS $1.87; 24/04/2018 – Ternium Files 2017 Form 20-F; 15/05/2018 – TERNIUM SA TX.N : CREDIT SUISSE RAISES TARGET PRICE TO $50 FROM $35.80; 02/05/2018 – Shareholders Approve All Resolutions on Agenda of Ternium’s Annual and Extraordinary General Meetings; 25/04/2018 – Ternium Expects Operating Income to Increase in 2Q Versus 1Q; 25/04/2018 – Ternium 1Q Operating Income Was $523.1 Million; 21/03/2018 Ternium Announces Annual and Extraordinary General Meetings of Shareholders; 25/04/2018 – TERNIUM SA QTRLY EARNINGS PER ADS $1.87; 10/04/2018 – Brazil steelmaker Usiminas says shareholders reach agreement; 11/04/2018 – Consolidated Research: 2018 Summary Expectations for Ternium S.A, CNB Financial, Barrick Gold, New York Mortgage Trust, Ascendi

Ternium S.A. (NYSE:TX) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *